Skip to main content

Table 3 Estimation of effectiveness against all-cause pneumonia for PCV13

From: Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan

  Proportion of all-cause pneumonia (%) Assumed VE
19A 12% 23.4% × 1.13
All other pneumonia 88% 23.4%
(Weighted) Total   23.8%
refer to calculation below   
VE 19A IPD 71% 80%
VE ratio, (PCV13:PHiD-CV) 1.13  
  1. Calculation of 1.13 as the VE ratio
  2. IPD invasive pneumococcal disease, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV 10-valent pneumococcal polysaccharide and NTHi protein D conjugate vaccine, VE vaccine effectiveness